Treatment with dopamine 2 receptor antagonists/partial agonists with antipsychotic the: A. Mesolimbic/mesostriatal pathway B. Mesocortical pathway C. Mesolimbic/mesostriatal and mesocortical pathways
A 44-year-old male with schizophrenia has been treated with a dopamine 2 receptor antagonist since initial diagnosis twelve years ago. He has recently begun experiencing difficulty with fluid movement of his arms as well as involuntary facial grimaces. Which of the following likely underlies these symptoms? A. Upregulation of serotonin 2A receptors B. Downregulation of serotonin 2A receptors
